Wilson's disease
ICD-10 E83.0 · ICD-11 5C64.00

Treatment of Wilson's Disease with Liver Cirrhosis, Fibrosis, Liver Failure, or Haemolysis

Clinical scenario

This protocol addresses Wilson's disease presenting with significant hepatic involvement — including liver cirrhosis significant liver fibrosis liver failure or haemolysis. These features indicate active copper-related organ injury requiring a specific first-line treatment approach.

Why this situation is distinct

In patients with significant liver disease — whether fibrosis, established cirrhosis, liver failure, or concurrent haemolysis — the choice of treatment strategy is guided by the severity of hepatic involvement. Guidelines specifically direct the first-line approach in this sub-population.

Treatment approach (overview)

Chelation therapy is the primary treatment in patients with significant liver disease in the context of Wilson's disease. Specific agents and their sequencing are detailed in the full protocol.

Full agent selection, dosing framework, and monitoring schedule available in the structured regimen →

Treatment goals
Instant Access to Structured Evidence-Based Regimens
References

DOI: 10.1016/j.jhep.2024.11.007

Chelators should be the primary choice in patients with significant liver disease, e.g. features of significant fibrosis and cirrhosis, liver failure, and haemolysis (LoE 3, strong recommendation, strong consensus).

View source ↗